KRAS and neoplasm: To investigate the clinical relevance of our findings, we performed BH3 profiling on KRAS-mutant NSCLCs (solid metastatic lesions or tumor cells isolated from malignant pleural effusions of patients) after ex vivo exposure to sotorasib or trametinib (Fig. 6A).